Redacted.

• Autores: Charles Seife
• Localización: Scientific American, ISSN 0036-8733, Vol. 318, Nº. 2, 2018, págs. 38-43
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The article reports that the U.S. Food and Drug Administration is seldom accused of being too transparent regarding certain important data about the performance of drugs and pharmaceutical companies . It mentions that FDA took the highly unusual step of approving a drug, eteplirsen, which is designed to help certain patients with Duchenne muscular dystrophy (DMD), against the advice of the agency's experts. It states that FDA made its adverse-events database easier to search.